Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

Abstract

A B S T R A C T PurposeWe report the experience with 2,000 consecutive patients with advanced cancer who underwent testing on a genomic testing protocol, including the frequency of actionable alterations across tumor types, subsequent enrollment onto clinical trials, and the challenges for trial enrollment. Patients and MethodsStandardized hotspot mutation analysis was performed in 2,000 patients, using either an 11-gene (251 patients) or a 46-or 50-gene (1,749 patients) multiplex platform. Thirty-five genes were considered potentially actionable based on their potential to be targeted with approved or investigational therapies. ResultsSeven hundred eighty-nine patients (39%) had at least one mutation in potentially actionable genes. Eighty-three patients (11%) with potentially actionable mutations went on genotypematched trials targeting these alterations. Of 230 patients with PIK3CA/AKT1/PTEN/BRAF mutations that returned for therapy, 116 (50%) received a genotype-matched drug. Forty patients (17%) were treated on a genotype-selected trial requiring a mutation for eligibility, 16 (7%) were treated on a genotype-relevant trial targeting a genomic alteration without biomarker selection, and 40 (17%) received a genotype-relevant drug off trial. Challenges to trial accrual included patient preference of noninvestigational treatment or local treatment, poor performance status or other reasons for trial ineligibility, lack of trials/slots, and insurance denial. ConclusionBroad implementation of multiplex hotspot testing is feasible; however, only a small portion of patients with actionable alterations were actually enrolled onto genotype-matched trials. Increased awareness of therapeutic implications and access to novel therapeutics are needed to optimally leverage results from broad-based genomic testing.

A Road Map for Precision Cancer Medicine Using Personalized Models

“…Less than 1% of samples had an alteration actionable with an FDA-approved drug. Although this study includes only patients with advanced disease, the small percentage of patients with therapeutically actionable molecular alterations is consistent with other studies from large patient cohorts (2). There is currently a lack of consensus in the community with respect to the interpretation of cancer variants and their potential actionability in the clinical setting.…”

DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?

“…Thus, BRAF V600E -mutant melanomas critically depend on increased MAPK pathway signaling, and hence such tumors respond well to selective inhibition of BRAF and/or MEK kinases (2)(3)(4). These and other encouraging results with targeted agents have sparked a number of histology-agnostic studies in which the presence of the oncogenic driver mutations is the sole selection criterion for treatment with the corresponding targeted agent in so-called basket studies (5)(6)(7). A first disappointment of these studies is that the number of "actionable" mutations (mutations for which a targeted drug is available as an approved indication or through a clinical trial) is relatively low.…”

Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie

“…Between 29-72% of patients had potentially actionable targets after sequencing with multiplex panels in results from several large cohorts (123)(124)(125)(126). The number of actionable targets is highly variable depending on the available compounds for treatment at a center and the number of mutations assessed in each panel.…”